Among 15 epigenetic regulators, we found that high expression of zinc finger (ZnF) CCHC domain-containing protein 4 (ZCCHC4) was correlated with poor prognosis of HCC patients, and ZCCHC4 was significantly upregulated in HCC cells after treatment of DNA-damage agents (DDAs) including oxaliplatin (OXA), a preferred chemotherapeutic agent for patients with advanced HCC.20 The results indicate that ZCCHC4 might be involved in modulating the chemoresistance of HCC cells to DDA. This evidence concerns the gene ZCCHC4 and hepatocellular carcinoma.